tazbentetol

Tazbentetol is an oral, first‑in‑class small‑molecule synaptic regenerative therapy being developed by Spinogenix to restore synaptic function in neurodegenerative and neuropsychiatric diseases including Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), schizophrenia, and potentially glaucoma.[5][1] Formerly known as SPG302, it is designed to trigger neurons to produce new glutamatergic synapses, thereby regenerating lost synaptic connections that underlie deficits in cognition, motor control, respiratory function, and sensory processing.[5][1][9] As an investigational, once‑daily therapy, tazbentetol has shown early signals of sustained cognitive benefit and favorable safety in Phase 2a studies in mild‑to‑moderate Alzheimer’s disease, and has advanced through mid‑stage development in ALS and schizophrenia with Orphan Drug Designation from both FDA and EMA for ALS.[3][5] The World Health Organization has approved “tazbentetol” as the International Nonproprietary Name for this active pharmaceutical ingredient, supporting its potential future commercialization as a novel disease‑modifying approach targeting synaptic loss rather than solely slowing neurodegeneration.[5][1]

Other names

Tazbentetol